Fig. 2From: Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART studyMean number of relapses in the pre- and post-treatment 12 monthsBack to article page